Acurx Pharmaceuticals Secures Streamlined FDA Path for Ibezapolstat

Key Facts

In a move that strengthens the outlook for clinical-stage biotech firms, Acurx Pharmaceuticals announced a successful regulatory consultation with the U.S. Food and Drug Administration (FDA). According to reports, the company received guidance allowing for the potential submission of a New Drug Application (NDA) for ibezapolstat based on a single Phase 3 clinical trial known as IBZ-ASPIRE. This clinical program targets C. difficile infections and the reduction of recurrence, marking a pivotal shift in the company's development strategy.

The regulatory guidance supports a streamlined path, as the FDA agreed that robust results from a single trial, supported by existing Phase 2 data, could suffice for a marketing approval filing. This decision is expected to significantly reduce R&D costs and time-to-market compared to traditional requirements that often necessitate two successful Phase 3 trials. Upon successful completion of the pivotal trial, Acurx plans to seek approval under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.

Regarding market performance, updated price data for the instrument is currently unavailable per market data as of August 3, 2026. Investors are closely watching the company's ability to meet the specific criteria of the IBZ-ASPIRE trial, as guidance indicates that failure to meet these benchmarks would require a second trial consistent with previous agreements reached in April 2024.